In a report published Thursday, Maxim Group analyst Jason Kolbert maintained a Buy rating on BioLine RX Ltd BLRX, with a price target of $8, ahead of the BL-1040 pivotal trial data in Europe, expected in the next few weeks.
BL-1040, known as bioabsorbable cardiac matrix or BCM, is "a novel, first-in-class device to prevent left ventricular remodeling and subsequent progression to congestive heart failure in patients who have had a heart attack (acute myocardial infarction)," the report said.
Bellerophon Therapeutics Inc BLPH, BiolineRx's partner for BL-1040, announced that all patients had completed follow-ups in June. If statistically significant, the final data may support registration in Europe as early as mid-2016. A US pivotal study is expected next year.
Analyst Jason Kolbert commented, "This is good news for both BiolineRx and Bellerophon. BL-1040 CE mark registration would result in BiolineRx shifting to a commercial stage company from solely development-stage. Combined we see a valuation inflection coming soon if the data is positive."
"We value BioLineRx based on the expected royalties from the products in late-stage development," Kolbert added.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in